Inventiva/$IVA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Inventiva
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.
Ticker
$IVA
Sector
Primary listing
Employees
116
Headquarters
Website
Inventiva Metrics
BasicAdvanced
$772M
-
-$3.61
0.61
-
Price and volume
Market cap
$772M
Beta
0.61
52-week high
$6.50
52-week low
$2.67
Average daily volume
59K
Financial strength
Current ratio
0.924
Quick ratio
0.903
Long term debt to equity
-95.626
Total debt to equity
-169.953
Interest coverage (TTM)
-1.13%
Profitability
EBITDA (TTM)
-113.381
Gross margin (TTM)
90.09%
Net profit margin (TTM)
-1,251.10%
Operating margin (TTM)
-651.45%
Effective tax rate (TTM)
-0.17%
Revenue per employee (TTM)
$152,430
Management effectiveness
Return on assets (TTM)
-63.60%
Return on equity (TTM)
265.67%
Valuation
Price to revenue (TTM)
20.872
Price to book
-4.24
Price to tangible book (TTM)
-4.24
Price to free cash flow (TTM)
-3.41
Free cash flow yield (TTM)
-29.32%
Free cash flow per share (TTM)
-1.692
Growth
Revenue change (TTM)
-38.24%
Earnings per share change (TTM)
26.56%
3-year revenue growth (CAGR)
18.36%
10-year revenue growth (CAGR)
8.64%
3-year earnings per share growth (CAGR)
34.47%
10-year earnings per share growth (CAGR)
15.22%
Bulls say / Bears say
Inventiva exceeded its enrollment targets in the pivotal Phase 3 NATiV3 trial, randomizing 1,009 patients in the main cohort and 410 in the exploratory cohort, advancing toward H2 2026 topline results (GlobeNewswire)
On May 5, 2025, Inventiva secured the second tranche of structured financing, raising €115.6 million gross (net €108.5 million) to fund NATiV3 and extend its operational runway (Euronext))
The dosing of the first participant in its Japan Phase 1 trial for lanifibranor, initiated on February 20, 2025 via the Hepalys partnership, expands Inventiva’s global development footprint (GlobeNewswire)
High cash burn leaves Inventiva with only €67.9 million after Q1 2025, projecting a runway only until Q3 2026 and necessitating further fundraising before pivotal NATiV3 readout (GlobeNewswire)
The May 5, 2025 structured financing issued 42.5 million new shares and attached warrants at €1.35, posing significant dilution risk to existing shareholders (Euronext))
Inventiva reported no revenues in Q1 2025 and faces a binary risk as topline Phase 3 NATiV3 results are not due until H2 2026, prolonging uncertainty and cash outflows (GlobeNewswire; GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 30 Aug 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Inventiva stock?
Inventiva (IVA) has a market cap of $772M as of September 13, 2025.
What is the P/E ratio for Inventiva stock?
The price to earnings (P/E) ratio for Inventiva (IVA) stock is 0 as of September 13, 2025.
Does Inventiva stock pay dividends?
No, Inventiva (IVA) stock does not pay dividends to its shareholders as of September 13, 2025.
When is the next Inventiva dividend payment date?
Inventiva (IVA) stock does not pay dividends to its shareholders.
What is the beta indicator for Inventiva?
Inventiva (IVA) has a beta rating of 0.61. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.